Furthermore, despite great advances in treating acute coronary syndromes and controlling risk factors leading to coronary artery disease, there is still an enormous need for further therapies as even with optimal medical treatment (including platelet inhibitors, beta blockers, ACE inhibitors and statins) the recurrent rate of acute coronary syndromes remains at 20% within 3 years (Cannon et al., 2005; Stone et al., 2011). The gene discussed is ACE; the disease is acute coronary syndrome.